Ginkgo Bioworks appoints Kathy Hopinkah Hannan to its Board of Directors

Ginkgo Bioworks Holdings, Inc.

Appointment effective August 2, 2022; term expires at 2023 annual meeting.
Received options to purchase Class A common stock valued at $400,000 plus prorated RSUs and options.
Eligible for $50,000 annual retainer and annual stock awards under Non-Employee Director Compensation Program.
Hannan is retired KPMG Vice Chair and serves on boards of NLY, OTIS, and CRS.
Board determined Dr. Hannan is independent under NYSE listing standards.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kathy Hopinkah Hannan

Director

DNA · Ginkgo Bioworks Holdings, Inc.

Effective: 2022-08-02
Filed: August 4, 2022, 7:59 PM ET

On August 2, 2022, the Board of Directors (the “Board”) of Ginkgo Bioworks Holdings, Inc. (the “Company”) voted to appoint Kathy Hopinkah Hannan to the Board, effective as of August 2, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kathy Hopinkah Hannan was appointed as Director at Ginkgo Bioworks Holdings, Inc..

Action: appointed
Role: Director

Exact text from the filing

On August 2, 2022, the Board of Directors (the “Board”) of Ginkgo Bioworks Holdings, Inc. (the “Company”) voted to appoint Kathy Hopinkah Hannan to the Board, effective as of August 2, 2022.

View on SEC.gov

Ginkgo Bioworks Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-014468

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.